Angiotensin Peptides Potentiate SARS-CoV-2 Spike Protein–AXL Interactions: Evidence and Implications

Study Background and Research Question

The renin-angiotensin system (RAS) is fundamental to cardiovascular homeostasis, with angiotensin peptides regulating blood pressure, vasoconstriction, and fluid balance. In parallel, the COVID-19 pandemic has revealed the crucial role of angiotensin-converting enzyme 2 (ACE2) as the primary entry receptor for SARS-CoV-2. However, AXL, a receptor tyrosine kinase, has emerged as an alternative spike protein receptor, especially in cell types with low ACE2 expression. The reference study by Oliveira et al. addresses a previously unexplored intersection: Can endogenous angiotensin peptides modulate SARS-CoV-2 spike protein binding to AXL and potentially influence viral entry or pathogenesis (paper)?

Key Innovation from the Reference Study

The innovation lies in systematically dissecting how various naturally occurring angiotensin peptides, including short C- and N-terminal fragments, affect the binding affinity of the SARS-CoV-2 spike protein to its known receptors—AXL, ACE2, and NRP1. Notably, the study discovers that several angiotensin fragments, such as angiotensin IV and angiotensin (5–7), significantly enhance spike–AXL binding, suggesting a direct mechanistic bridge between classical RAS signaling and viral-host cell interactions (paper).

Methods and Experimental Design Insights

Oliveira et al. utilized antibody-based binding assays to quantify the interaction between the SARS-CoV-2 spike protein and its receptors in the presence of various angiotensin peptides. Peptides analyzed included angiotensin I (1–10), angiotensin II (1–8), angiotensin (1–7), (1–6), as well as N-terminally truncated forms such as angiotensin III (2–8), IV (3–8), (2–7), and (5–7) (the H2N-Ile-His-Pro-OH peptide). Modifications at position 4 (tyrosine to valine substitution or phosphorylation) were also examined to elucidate structure–activity relationships. The use of defined peptide fragments allowed precise mapping of sequence features critical for spike binding enhancement.

Protocol Parameters

• binding assay | antibody-based ELISA | spike-AXL, spike-ACE2, spike-NRP1 | enables quantification of peptide-mediated effects on receptor engagement | paper
• peptide concentration | 1–10 μM (typical) | peptide–receptor interaction studies | ensures physiologically relevant range for peptide activity | paper
• peptide solubility | ≥50 mg/mL in water | solution preparation for in vitro assays | supports high-throughput screening and experimental reproducibility | product_spec
• storage condition | –20°C (solid) | peptide stability | preserves peptide integrity and activity for repeated use | workflow_recommendation

Core Findings and Why They Matter

The study demonstrates several mechanistically important points:

• Angiotensin II (1–8) increases spike–AXL binding by approximately two-fold, with no effect on ACE2 or NRP1 interactions (paper).
• Shorter peptides derived from angiotensin II—specifically those with N-terminal truncations (e.g., angiotensin IV (3–8), angiotensin (5–7))—produce an even more pronounced enhancement, up to 2.7-fold for angiotensin IV.
• Structure–activity relationships: C-terminal deletions like angiotensin (1–7) retain or enhance this effect, whereas N-terminal deletions potentiate it further, pinpointing sequence determinants of spike–AXL interaction potentiation.
• Tyrosine modifications at position 4 of angiotensin II also boost spike–AXL binding, highlighting specific residue importance.
• Some peptides, notably angiotensin IV, also enhanced spike binding to ACE2 and NRP1, suggesting broader modulation of viral entry routes.

These findings reveal that RAS–derived peptides, especially short N-terminal fragments like H2N-Ile-His-Pro-OH (angiotensin (5–7)), may act as endogenous enhancers of viral receptor engagement, potentially influencing tissue susceptibility and COVID-19 disease dynamics (paper).

Comparison with Existing Internal Articles

Several internal resources expand on the physiological and experimental relevance of angiotensin (5–7):

• "Angiotensin 1/2 (5-7): Precision Peptide for RAS & Viral ..." highlights the peptide's solubility and vasoconstrictor activity, supporting reproducible workflows in both cardiovascular and SARS-CoV-2 research domains. This aligns with the reference paper’s evidence that H2N-Ile-His-Pro-OH fragments directly modulate viral-receptor interactions.
• "Angiotensin 1/2 (5-7): A Precision Vasoconstrictor Peptid..." details the biological rationale for using angiotensin (5–7) in blood pressure and viral pathogenesis models, reinforcing its utility as both a blood pressure regulation peptide and a probe for angiotensin signaling pathway effects.

Compared to internal articles, the reference study is the first to provide direct experimental evidence for angiotensin (5–7) and related fragments as enhancers of SARS-CoV-2 spike–AXL binding, opening a new functional perspective on their role in COVID-19 research.

Limitations and Transferability

While the study's in vitro binding assays offer clear mechanistic insight, several limitations must be noted:

• The experiments were conducted using recombinant proteins and synthetic peptides, which may not fully recapitulate in vivo peptide concentrations, post-translational modifications, or tissue-specific contexts (paper).
• Functional consequences for viral infectivity or disease progression were not directly assessed, so the clinical significance of enhanced binding remains to be determined.
• Transferability to other coronaviruses or broader viral systems is not established and should be approached cautiously.

Why this cross-domain matters, maturity, and limitations

The cross-domain insight—that a classical blood pressure regulation peptide (angiotensin (5–7)) modulates viral entry processes—underlines the complexity of COVID-19 pathogenesis at the interface of cardiovascular and infectious disease biology. While mechanistic maturity is high for the observed receptor binding effects, translation to therapeutic or diagnostic applications will require further in vivo and clinical validation. The reference evidence should prompt careful consideration in both hypertension research peptide workflows and viral pathogenesis models, but is not yet actionable for patient care (paper).

Research Support Resources

For laboratories wishing to replicate or extend these findings, high-purity angiotensin peptides are essential for assay reproducibility. Angiotensin 1/2 (5-7) (SKU A1049) from APExBIO, with the sequence H2N-Ile-His-Pro-OH, offers validated purity and solubility suitable for both RAS and spike–receptor binding studies (product_spec). This peptide can streamline experimental workflows in renin-angiotensin system research, blood pressure regulation assays, and SARS-CoV-2 mechanistic studies. For detailed protocols and scenario-driven guidance, researchers may reference internal articles such as Reliable Peptide for Reproducible Assays or Advanced RAS Research.